Our new generation of fusion proteins enhance therapeutic efficacy by stimulating endogenous anticancer immunity within the solid tumor microenvironment.
We are developing a toolbox of TSRs and will determine which ones best enhance therapeutic efficacy against hematological and solid tumors, to support clinical translation.
We are developing a new class of fusion proteins, called Dual Costimulatory Receptors (DCR), that combine a costimulatory ligand ectodomain with a different costimulatory signaling endodomain.
